Alzheimer’s: New Drug Reprograms Brain Cells, Shows Promise in Animal Studies
Barcelona, Spain – Researchers at the University of Barcelona have developed and validated a novel compound, FLAV-27, that demonstrates the potential to reverse cognitive impairment in animal models of Alzheimer’s disease. Unlike existing treatments that primarily focus on removing amyloid plaques, this experimental drug targets the underlying epigenetic mechanisms contributing to the disease’s progression, offering … Read more